Liraglutide treatment is associated with progression of coronary artery fibrous plaque: a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes.
Coronary atherosclerosis
Coronary computed tomography angiography
Glucagon-like peptide 1 receptor agonist
Liraglutide
Type 2 diabetes mellitus
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
28 04 2023
28 04 2023
Historique:
received:
12
12
2022
accepted:
05
04
2023
medline:
1
5
2023
pubmed:
29
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
The objective of this study was to assess the association between clinically indicated liraglutide treatment and coronary artery plaque progression during 1-year follow-up in asymptomatic diabetes. Patients were divided into a group receiving liraglutide (Lira+) and a group not receiving liraglutide (Lira-). Coronary computed tomography angiography (CCTA) was performed to assess total atheroma volume (TAV) and subtypes of plaque volumes (dense calcium, fibrous, fibrous-fatty, and necrotic core plaque) and the plaque progression during one year follow-up. Fifty-five patients (27%) receiving liraglutide and 149 (73%) how did not were included. Changes in TAV during 1-year of follow-up were similar in the two groups (38 ± 180 (Lira+) vs. -1 ± 160 mm In patients with T2D without known prior coronary artery disease, liraglutide treatment was associated with a significant increase in coronary artery fibrous plaque volume during 1-year follow-up.
Identifiants
pubmed: 37118678
doi: 10.1186/s12872-023-03228-5
pii: 10.1186/s12872-023-03228-5
pmc: PMC10148401
doi:
Substances chimiques
Liraglutide
839I73S42A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
214Informations de copyright
© 2023. The Author(s).
Références
J Biol Chem. 1986 Feb 25;261(6):2810-3
pubmed: 3005265
Int J Cardiovasc Imaging. 2011 Apr;27(4):593-600
pubmed: 20820922
JAMA. 2004 Mar 3;291(9):1071-80
pubmed: 14996776
Atherosclerosis. 2019 Sep;288:60-66
pubmed: 31326727
JAMA. 2006 Apr 5;295(13):1556-65
pubmed: 16533939
Circ Cardiovasc Imaging. 2018 Jan;11(1):e006973
pubmed: 29305348
N Engl J Med. 1997 May 1;336(18):1276-82
pubmed: 9113930
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
Mol Cell Endocrinol. 2010 Aug 30;325(1-2):26-35
pubmed: 20452396
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Diab Vasc Dis Res. 2013 Jul;10(4):353-60
pubmed: 23673376
JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857
pubmed: 30623143
Diabetes Obes Metab. 2019 Aug;21(8):2012-2016
pubmed: 31050161
Int J Cardiovasc Imaging. 2013 Jun;29(5):1177-90
pubmed: 23417447
Diabetologia. 2009 Nov;52(11):2337-44
pubmed: 19680627
Clin Radiol. 2013 Oct;68(10):1054-8
pubmed: 23809270
Atherosclerosis. 2013 Dec;231(2):427-35
pubmed: 24267262
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S28-37
pubmed: 22421228
Cardiovasc Diabetol. 2017 Nov 6;16(1):143
pubmed: 29110715
N Engl J Med. 1995 Nov 16;333(20):1301-7
pubmed: 7566020
J Cardiovasc Comput Tomogr. 2014 Sep-Oct;8(5):342-58
pubmed: 25301040
Atherosclerosis. 2015 Aug;241(2):579-87
pubmed: 26115069